PMID- 36841985
OWN - NLM
STAT- MEDLINE
DCOM- 20230228
LR  - 20230228
IS  - 1565-1088 (Print)
VI  - 25
IP  - 2
DP  - 2023 Feb
TI  - Type 2 Diabetes Mellitus: GLP1 Receptor Agonists and SGLT2 Inhibitors in Patients 
      Referred to Ambulatory Consultant Cardiology Clinics.
PG  - 143-146
AB  - BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like 
      peptide-1 receptor agonists (GLP1-RA) are new antidiabetic drugs that are 
      recommended by current guidelines as a class I novel glucose-lowering treatment 
      that improves cardiovascular outcome in type 2 diabetes mellitus (T2DM), 
      particularly in patients with cardiovascular disease. OBJECTIVES: To evaluate 
      adherence to the current guidelines for treatment with SGLT2i and GLP1-RA drugs 
      in patients referred to ambulatory consultant cardiology clinics with 
      pre-existing T2DM. METHODS: We studied consecutive new patients with a 
      pre-existing diagnosis of T2DM who were referred to the Clalit Health Services 
      ambulatory consultant cardiology clinic over a 6-month period. The recorded 
      information included demographics, co-morbidities, and prescribed drugs at 
      patient admission. RESULTS: During the study period, 1782 patients visited our 
      outpatient cardiology clinic. At screening, T2DM was present in 428 patients 
      (24%); 77 (18%) were being treated with SGLT2i, and 39 (9.1%) with GLP1-RA. 
      Patients receiving SGLT2i and GLP1-RA were younger and had more coronary artery 
      disease, lower mean left ventricular ejection fraction, and higher mean estimated 
      glomerular filtration rates than those who were not receiving these drugs. HbA1C 
      was > 7 in 205 (47.9%) patients and > 7.5 in 136 patients (31.8%). Body mass 
      index was > 30 kg/m2 in 231 (54%) patients. CONCLUSIONS: GLP1-RA and SGLT2i drugs 
      were found to be administered more frequently than previously reported, but they 
      are not yet satisfactorily prescribed.
FAU - Antonelli, Dante
AU  - Antonelli D
AD  - Department of Cardiology, Emek Medical Center, Afula, Israel.
FAU - Rabkin, Youri
AU  - Rabkin Y
AD  - Department of Cardiology, Emek Medical Center, Afula, Israel.
FAU - Turgeman, Yoav
AU  - Turgeman Y
AD  - Department of Cardiology, Emek Medical Center, Afula, Israel.
FAU - Jabaren, Mohamed
AU  - Jabaren M
AD  - Department of Cardiology, Emek Medical Center, Afula, Israel.
LA  - eng
PT  - Journal Article
PL  - Israel
TA  - Isr Med Assoc J
JT  - The Israel Medical Association journal : IMAJ
JID - 100930740
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy/epidemiology
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Consultants
MH  - Stroke Volume
MH  - Ventricular Function, Left
MH  - Hypoglycemic Agents/therapeutic use
MH  - Glucose/therapeutic use
MH  - *Cardiology
EDAT- 2023/02/27 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/02/26 06:03
PHST- 2023/02/26 06:03 [entrez]
PHST- 2023/02/27 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
PST - ppublish
SO  - Isr Med Assoc J. 2023 Feb;25(2):143-146.